Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scandinavian Real Heart ABFRA:7820 +4.00%30 Debt-to-EBITDA is -0.24 as of Jun. 2026. GuruFocus rates FRA:7820 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Scandinavian Real Heart AB ranks worse than 212314.01% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Scandinavian Real Heart AB's Debt-to-EBITDA or its related term are showing as below:
FRA:7820'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69 Med: -0.29 Max: -0.12
Current: -0.25
During the past 13 years, the highest Debt-to-EBITDA Ratio of Scandinavian Real Heart AB was -0.12. The lowest was -0.69. And the median was -0.29.
FRA:7820's Debt-to-EBITDA is ranked worse than 100% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:7820: -0.25
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Scandinavian Real Heart AB Debt-to-EBITDA Related Terms
Scandinavian Real Heart AB Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7820 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Scandinavian Real Heart AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scandinavian Real Heart AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scandinavian Real Heart AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scandinavian Real Heart AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Scandinavian Real Heart AB (FRA:7820) has a Debt-to-EBITDA of -0.24 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scandinavian Real Heart AB. According to the industry distribution chart, Scandinavian Real Heart AB ranks #999999 out of 471 companies in the Medical Devices & Instruments industry.
Is Scandinavian Real Heart AB's Debt-to-EBITDA too high?
Scandinavian Real Heart AB's current Debt-to-EBITDA is -0.24. Based on the distribution chart, Scandinavian Real Heart AB ranks #999999 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Scandinavian Real Heart AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Scandinavian Real Heart AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Scandinavian Real Heart AB ranks #999999 out of 471 companies for Debt-to-EBITDA. This places Scandinavian Real Heart AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scandinavian Real Heart AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scandinavian Real Heart AB's current Debt-to-EBITDA is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scandinavian Real Heart AB stock overvalued right now?
Scandinavian Real Heart AB (FRA:7820) has a current Debt-to-EBITDA of -0.24. The current Debt-to-EBITDA is -0.24. Scandinavian Real Heart AB's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Scandinavian Real Heart AB (FRA:7820), the current Debt-to-EBITDA is -0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scandinavian Real Heart AB is engaged in developing an artificial heart that mimics the shape, function, and bloodflow pattern of the human heart. The company conducts research and development in medical technology and is developing an artificial heart that mimics the function of a natural heart - a so-called total artificial heart (TAH), Realhear, TAH. It is a Swedish-patented product that saves lives and improves the quality of life.
30GF Score
Get the complete analysis for FRA:7820
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7820 has been successfully added to your 
